If technology was earnings season’s problem child, pharmaceuticals were its star pupil. Regeneron headlined a strong run of drugmaker results, reporting third-quarter revenue up 36 per cent to $5.1 billion and adjusted earnings of $20.07 a share, numbers that sent its stock sharply higher.
Blockbusters doing the work
Regeneron’s growth was powered by its flagship treatments, including the eczema and asthma drug Dupixent and its eye medicine Eylea HD, which continue to expand into new patient groups. The company was not alone: AbbVie raised its full-year outlook after revenue rose 10.3 per cent to $17.4 billion, while AstraZeneca and Sanofi both traded higher after their disclosures. Colgate-Palmolive added a consumer-staples gloss, raising its sales and profit guidance. The defensive pattern of the week is one our economy coverage flagged as investors rotated out of growth stocks.
Why pharma is the market’s shelter
Drug demand does not depend on consumer confidence in the way advertising or cloud subscriptions do, and the sector’s patent-protected cash flows look especially attractive when bond yields and oil prices are both rising. That made healthcare a natural home for money leaving technology, and the week’s results gave that rotation fundamental support rather than mere fashion.
The week in one dashboard
The broader picture, index levels, sector moves and the macro data that accompanied the earnings, from employment costs to the Chicago PMI, is pulled together in this daily market wrap. It captures a market that ended the week flatter than the headlines suggest, because the sectors falling and rising largely cancelled each other out.
There is a structural reason drugmakers keep delivering quarters like this: the industry’s best products are protected monopolies with inelastic demand, and the current generation of blockbusters, in immunology, eye disease, obesity and oncology, is still expanding into new indications and new countries. Regeneron’s rise also reflects a research model that keeps producing follow-on products from its own platforms rather than buying growth at auction prices. The risks are real but slower-moving: patent cliffs later in the decade, pricing politics in the United States and the occasional clinical failure. Against a market sell-off measured in days, those are comfortable problems to have, which is precisely why the sector absorbed so much defensive money this week.
Earnings seasons are remembered for their defining stocks. This one may be remembered for a rotation: out of the AI trade and into companies selling medicine, toothpaste and petrol. Regeneron’s quarter is the clearest evidence yet that the boring end of the market is having its moment.
